Chr. Hansen Holding A/S Interim Report Q1 2022/23
January 12, 2023 – Company announcement no. 1
Solid Q1 supports the outlook for 2022/23
Statement by CEO Mauricio Graber: “The solid results for Q1 show the strength of our business model. Organic growth reached 10%, driven by both volume and pricing initiatives and EBIT b.s.i. increased by 17% supported by the organic growth and exchange rates, leading to an EBIT margin b.s.i. of 24.7%. In light of the Q1 performance we maintain our underlying target for the year but update the outlook to reflect current exchange rate levels.
We will maintain a clear and strong focus on executing on our targets for the financial year 2022/23 while preparing for the proposed merger with Novozymes, which offers an exciting opportunity to create a leading global biosolutions partner based on strong complementary technology platforms, highly dedicated employees and a customer-centric approach.”
Q1 2022/23 highlights
- Revenue amounted to EUR 310 million, up 15% from EUR 268 million in Q1 2021/22.
- Organic growth was 10% in Q1 2022/23 driven by a mix of volume and price growth. Food Cultures & Enzymes organic growth was 8% mainly driven by price initiatives, but with good volume growth above underlying markets. Health & Nutrition organic growth was 12% driven by volume. The Lighthouses (Bioprotection, Fermented Plant Bases, Plant Health and HMO) was impacted by timing of orders and delivered 4% organic growth combined in Q1, while the core businesses delivered 10% organic growth.
- EBIT b.s.i. amounted to EUR 77 million, up 17% from EUR 65 million in Q1 2021/22. The increase was driven by a positive contribution from exchange rates and pricing initiatives, which was partly offset by a negative impact from higher input costs.
- The EBIT margin b.s.i. was 24.7%, up from 24.4% in Q1 2021/22. The improved margin was due to a positive contribution from exchange rates, which was partly offset by continuing inflationary pressures, despite ongoing price initatives.
- Free cash flow b.a.s.i. amounted to EUR 17 million, down from EUR 55 million last year, as the cash flow from operating activities b.a.s.i. was negatively impacted by a change in working capital and higher taxes paid.
- On December 12, 2022 Chr. Hansen and Novozymes announced that the two companies had entered into an agreement to create a leading global biosolutions partner through a statutory merger. Work has been initiated to seek customary merger control and other regulatory approvals from relevant authorities, while the extraordinary general meeting for shareholder approval is currently expected to be held in the first half of the calendar year 2023.
The current exchange rate level for the EUR/USD stands at 1.07 versus 0.97 at the time of the initial 2022/23 outlook provided on October 12, 2022. To reflect the 10% depreciation of the USD we update the outlook for the year regarding the impact from exchange rates on revenue, EBIT margin b.s.i. and cashflow b.a.s.i. The expectations to the underlying business incl. organic growth, EBIT margin b.s.i. and cash flow b.a.s.i. net of exchange rates remain unchanged.
- Organic revenue growth is expected in the range of 7-10% (unchanged)
- Impact from exchange rates on revenue will be neutral (previously positive 5%)
- EBIT b.s.i. is expected to grow in line with revenue (previously faster than revenue)
- EBIT margin b.s.i. is expected to be 26-27% (previously 27-28%)
- Free cash flow b.a.s.i. is expected to be around EURm 170-210 (previously EURm 190-230)
The outlook for 2022/23 is based on actual exchange rates until January 11, 2023, and for the remainder of the year assuming constant exchange rates at the current level of EUR/USD rate of 1.07. For further details on the outlook for 2022/23, please refer to page 10.
See attachment for full Q1 2022/23 interim report.
Anders Mohr Christensen, VP Group Strategy & Investor Relations, +45 25 15 23 64
Cristina Rønde Hefting, Senior Investor Relations Manager, +45 40 72 12 24
About Chr. Hansen
Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen, we are strongly positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends, we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As the world’s most sustainable food ingredients company, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nikkiso Clean Energy & Industrial Gases Group Announces Expansion of Service for Middle East and Northern Africa30.1.2023 23:49:26 CET | Press release
TEMECULA, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Nikkiso Clean Energy & Industrial Gases Group (“Group”), a part of the Nikkiso Co., Ltd (Japan) group of companies, is proud to announce yet another expansion of their manufacturing and service capabilities for the Middle East and Northern Africa markets. With this expansion, they will be providing pump and turboexpander aftermarket repairs of their full line, including J.C. Carter pumps. Their new state-of-the-art service center will allow repairs to be made locally rather than the need to ship elsewhere. The new facility, based in the Sharjah Free Zone, was established to provide expanded support for the Middle East and Northern Africa markets. They have added field service support, and shop technicians specifically trained to support Marine, J.C. Carter, Nikkiso Cryogenic Pumps (ACD and Nikkiso Cryo) and Turboexpanders. In addition to in-shop and on-site repairs, they will provide aftermarket service. “With this facility, we will b
Constellation Brands Prices Offering of Senior Notes30.1.2023 22:40:18 CET | Press release
VICTOR, N.Y., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that it priced the public offering of $500.0 million aggregate principal amount of 5.000% Senior Notes due 2026 (the “notes”) for a public offering price of 99.829% of the principal amount of the notes. The notes will be senior obligations that rank equally with all of Constellation’s other senior unsecured indebtedness. Closing of the offering is expected to occur on February 2, 2023. Constellation intends to use the net proceeds from the offering for general corporate purposes, including the repayment of a portion of its indebtedness outstanding under the delayed draw three-year term loan facility of its term loan credit agreement, dated as of August 9, 2022, as amended on October 18, 2022. BofA Securities, Inc., Goldman Sachs & Co. LLC, and J.P. Morgan Securities LLC are acting as the joint book-running managers of the offering. The notes are be
Nokia Corporation: Repurchase of own shares on 30.01.202330.1.2023 20:00:00 CET | Press release
Nokia Corporation Stock Exchange Release 30 January 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 30.01.2023 Espoo, Finland – On 30 January 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL279,9364.37CEUX20,9634.38AQEU7,9574.36TQEX6,3444.39Total315,2004.37 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023
Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group30.1.2023 18:00:00 CET | Press release
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the conversion of convertible bonds that have been issued to Negma in accordance with the financing agreement announced by Mendus through press releases on 26 August and 26 October 2022. Negma has requested conversion of two (2) convertible bonds issued on 3 January 2023, corresponding to SEK 50,000 of the convertible loan amounting to a total of SEK 13,700,000, into 20,325 shares. Upon registration at the Swedish Companies Registration Office, Mendus’ total share capital will amount to SEK 9,971,046.20 and the total number of shares and votes will amount to 199,420,924. The conversion price per share is SEK 2.46, equivalent to 92% of the second lowest closing volume weighted average share price (VWAP) of the 10 consecutive trading days preceding the issuance of conversion request by Negma. F
Mendus AB: Mendus tillkännager begäran från Negma Group om konvertering av konvertibla skuldebrev30.1.2023 18:00:00 CET | Pressemelding
Mendus AB (“Mendus” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på immunterapier mot tumöråterfall, tillkännager idag att Negma Group (”Negma”) genom meddelande till Mendus har begärt konvertering av konvertibla skuldebrev som utfärdats till Negma i enlighet med det finansieringsavtal som Mendus tillkännagivit genom pressmeddelanden den 26 augusti och 26 oktober 2022. Negma har begärt konvertering av två (2) konvertibla skuldebrev som emitterades den 3 januari 2023, motsvarande 50 000 kronor av det konvertibla lånet som uppgår till totalt 13 700 000 kronor, till 20 325 aktier. Efter registrering hos Bolagsverket kommer Mendus totala aktiekapital att uppgå till 9 971 046,20 kronor och det totala antalet aktier och röster kommer att uppgå till 199 420 924. Konverteringspriset per aktie är 2,46 kronor, motsvarande 92% av det näst lägsta dagliga volymvägda genomsnittliga aktiekursen (VWAP) under de 10 på varandra följande handelsdagarna före konverteringsbegäran från Negma. För ytte